Chronic Rhinosinusitis

Clinical Study of NEUROMARK System in Patients with Chronic Rhinosinusitis (CRS)

To qualify for this study, potential study participants must:

• Be 18 years and older
• Have been diagnosed with CRS for at least 12 weeks, with 2 or more of the following sinus symptoms:
  • mucopurulent drainage (anterior, posterior, or both)
  • nasal obstruction (congestion)
  • facial pain/pressure/fullness
  • decreased sense of smell
• Have a qualifying CT scan within the last 6 months showing at least 25% opacification of ethmoid sinuses and at least 25% opacification of at least 1 maxillary sinus.
• Have been nonresponsive to medical management (trial of antibiotics; plus trial of oral/nasal corticosteroids).

Chronic Rhinosinusitis With Nasal Polyps

The CONTRAST-NP research study is assessing an investigational medicine for Chronic Rhinosinusitis with Nasal Polyps.

To qualify for this study, potential study participants must:

• Be 18 years and older
• Have been diagnosed with Chronic Rhinosinusitis with nasal polyps in both sides of your nose (bilateral)
• Have had treatment in past two years with (or are intolerant of) systemic corticosteroids and/or have had nasal polyp surgery
• Have ongoing symptoms such as nasal congestion for at least 8 weeks prior to study screening

Ibuzatrelvir

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With Coronavirus Disease 2019 (COVID-19) Who Are Not Hospitalized But Are at Risk For Severe Disease

1. 12 to <18 years of age, weighing at least 40 kg, or ≥18 years of age of any weight at screening.
2. Presence of risk factors for progression to severe COVID-19 at the time of screening based on age:
• 12 to 49 years of age with at least two risk factors, where one must be moderate immunocompromise;
• 50 to 64 years of age with at least two risk factors;
• 65 to 74 years of age with at least one risk factor;
• For participants 75 years of age or older, there are no requirements related to risk factors.